Skip to main content
Figure 2 | Cancer Cell International

Figure 2

From: Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)

Figure 2

SDS-PAGE (15% gel) analysis of native and mPEG-SPA pegylated rhArg11. Time-course of the pegylation reaction with 1:20 and 1:50 (mol/mol) of rhArg11:mPEG-SPA. Lane 1, low-range protein marker; Lane 2, native rhArg1; Lane 3, 1:20 mole ratio (0.5 h); Lane 4, 1:20 mole ratio (1 h); Lane 5, 1:20 mole ratio (2 h); Lane 6, 1:20 mole ratio (3 h); Lane 7, 1:20 mole ratio (20 h); Lane 8, 1:50 mole ratio (0.5 h); Lane 9, 1:50 mole ratio (1 h); Lane 10, 1:50 mole ratio (2 h); Lane 11, 1:50 mole ratio (3 h); Lane 12, 1:50 mole ratio (20 h).

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us